Corteva (CTVA)
(Delayed Data from NYSE)
$53.96 USD
+0.43 (0.80%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $53.98 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CTVA 53.96 +0.43(0.80%)
Will CTVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CTVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTVA
Wall Street Bulls Look Optimistic About Corteva, Inc. (CTVA): Should You Buy?
Cibus (CBUS) Moves 6.7% Higher: Will This Strength Last?
CTVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corteva, Inc. (CTVA) Stock Moves -0.2%: What You Should Know
Corteva, Inc. (CTVA) Gains But Lags Market: What You Should Know
Zacks Industry Outlook Highlights Corteva, Dole and Alico
Other News for CTVA
MOO ETF: Agriculture Stocks Are Inexpensive and Defensive
GUNR ETF: Diversified Access to Surging Commodities Stocks
GUNR ETF: Diversified Access to Surging Commodities StocksĀ
Corteva cut at J.P. Morgan, seeing weak Q1 earnings on lower crop chemical prices
Corteva cut at J.P. Morgan, expecting Q1 earnings weakness